Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS
Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.
Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial
Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.
